A 48-year-old man with biopsy-confirmed pemphigus vulgaris is being monitored for disease activity and treatment response. Which investigation is most useful for assessing disease severity and predicting the extent of mucocutaneous involvement?

Explanation

## Serum Anti-Desmoglein Antibody Titre in Pemphigus Vulgaris **Key Point:** Serum anti-desmoglein (anti-Dsg) antibody titre by ELISA is the most useful investigation for assessing disease activity, predicting severity, and monitoring treatment response in pemphigus vulgaris. ### Pathogenic Role of Anti-Dsg Antibodies Pemphigus vulgaris is an **IgG-mediated autoimmune disorder** targeting desmogleins (Dsg), which are adhesion molecules on keratinocytes. The pattern of antibodies determines clinical phenotype: | Antibody Profile | Clinical Phenotype | Severity | | --- | --- | --- | | **Anti-Dsg3 alone** | Mucosal-dominant (oral erosions ± limited skin) | Milder | | **Anti-Dsg3 + Anti-Dsg1** | Mucocutaneous (oral + extensive skin) | More severe | | **Anti-Dsg1 alone** | Superficial pemphigus foliaceus (rare in vulgaris) | Variable | **High-Yield:** Anti-Dsg3 titre correlates with: - Disease activity and flare severity - Extent of mucocutaneous involvement - Response to immunosuppressive therapy - Prognosis and need for escalation of treatment ### Clinical Utility of Anti-Dsg Antibody Titre **Mnemonic:** **ELISA = Enzyme-Linked ImmunoSorbent Assay** — quantifies antibody titre, not just presence/absence. 1. **Prognostic value**: Higher anti-Dsg3 titre at diagnosis predicts more extensive disease 2. **Activity marker**: Titre correlates with number of active lesions 3. **Treatment monitoring**: Declining titre indicates therapeutic response 4. **Relapse prediction**: Rising titre may herald impending flare before clinical manifestations 5. **Remission assessment**: Persistently low or undetectable titre suggests sustained remission ### Why Anti-Dsg Antibody Titre Is Superior for Monitoring ```mermaid flowchart TD A[Pemphigus Vulgaris Diagnosed]:::outcome --> B[Measure serum anti-Dsg3 and anti-Dsg1 titre]:::action B --> C{Titre level and pattern?}:::decision C -->|High anti-Dsg3 ± anti-Dsg1| D[Predict mucocutaneous involvement]:::action C -->|Anti-Dsg3 alone| E[Expect mucosal-dominant disease]:::action D --> F[Start immunosuppression]:::action E --> F F --> G[Repeat serum anti-Dsg titre at 4–6 weeks]:::action G --> H{Titre declining?}:::decision H -->|Yes| I[Treatment effective, continue]:::action H -->|No or rising| J[Inadequate response, escalate therapy]:::urgent J --> K[Repeat anti-Dsg titre in 4 weeks]:::action K --> H ``` **Clinical Pearl:** A single negative or low anti-Dsg titre does not exclude pemphigus vulgaris (5–10% of patients are seronegative); however, in seropositive patients, serial titres are highly valuable for monitoring. ### Why Other Investigations Are Not Optimal for Monitoring | Investigation | Limitation for Monitoring | | --- | --- | | **H&E histopathology (repeat)** | Invasive, time-consuming, histology does not change as rapidly as clinical activity; acantholysis persists even during remission | | **Tzanck smear** | Non-specific, operator-dependent, does not quantify disease burden or predict flares | | **DIF (repeat)** | Remains positive even during clinical remission; does not reflect current disease activity; invasive | **Warning:** Do NOT rely on repeat DIF or histology for monitoring — these remain positive long after clinical remission and do not guide treatment adjustments.